zofistar plus
menarini international operations luxembourg s.a. - zofenoprilio kalcio druska/hidrochlorotiazidas - plėvele dengtos tabletės - 30 mg/12,5 mg - zofenopril and diuretics
dolmen
menarini international operations luxembourg s.a. - deksketoprofenas - geriamasis tirpalas paketėlyje - 12,5 mg; 50 mg/2 ml; 25 mg - dexketoprofen
lioton
a.menarini industrie farmaceutiche riunite s.r.l. - heparino natrio druska - gelis - 1000 tv/g - heparin
dolmen
menarini international operations luxembourg s.a. - deksketoprofenas - granulės paketėlyje - 25 mg - dexketoprofen
opexa
menarini international operations luxembourg s.a. - bilastinas - burnoje disperguojamos tabletės - 20 mg - bilastine
orserdu
stemline therapeutics b.v. - elacestrant - krūties navikai - endokrininė terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
mirelle
bayer pharma ag - gestodenas/etinilestradiolis - plėvele dengtos tabletės - 60 µg/15 µg - gestodene and ethinylestradiol
natrio fluoridas (18f) life radiopharma
life radiopharma berlin gmbh - natrio fluoridas (18f) - injekcinis tirpalas - 0,1-4 gbq/ml - sodium fluoride (18f)
fludeoxyglucose (18f) life radiopharma
life radiopharma berlin gmbh - fludeoksigliukozė (18f) - injekcinis tirpalas - 300-3100 mbq/ml - fludeoxyglucose (18f)
invokana
janssen-cilag international nv - kanagliflozinas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5.